Radio
Now Playing
Quickyla Radio โ€” Click to play
Open โ†’
3 min left

Sanofi considers acquiring Insmed to diversify amid Dupixent patent expiration

Sanofi is considering acquiring Insmed Inc. to diversify its portfolio as its blockbuster drug Dupixent faces patent expiration. Insmed's strong respiratory products, like Brinsupri and Arikayce, preโ€ฆ

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed
Benzinga โ€” 19 November 2026
Text:
2 0 0

Insmed Inc. saw its stock price soar on Thursday after reports emerged that French pharmaceutical company Sanofi is considering acquiring the respiratory disease specialist. This potential acquisition comes as Sanofi, under new CEO Belรฉn Garijo, seeks to diversify its portfolio and reduce its dependence on its blockbuster drug Dupixent, which is facing patent expiration.

Sanofi's interest in Insmed reflects a broader trend in the pharmaceutical industry where companies are actively seeking new growth opportunities amid increasing competition and the looming loss of exclusivity on key products. Dupixent has been a significant revenue driver for Sanofi, but as its patent clock ticks down, the company is exploring strategic acquisitions to bolster its future pipeline. According to sources cited in Bloomberg, Sanofi is currently working with financial advisers to assess the potential acquisition of Insmed.

Insmed offers two commercialized respiratory drugs: Brinsupri, which treats non-cystic fibrosis bronchiectasis, and Arikayce, aimed at patients with refractory Mycobacterium avium complex (MAC) lung disease. In the third quarter, Brinsupri alone generated sales of $400.1 million, showcasing its strong market potential. The growth of these products could make Insmed an attractive target for Sanofi as it seeks to expand its respiratory portfolio.

If the acquisition proceeds, it could reshape the competitive landscape in the respiratory market. For Sanofi, acquiring Insmed would mean not only enhancing its product offerings but also gaining access to valuable expertise in respiratory diseases. The move underscores the increasing urgency for pharmaceutical companies to innovate and adapt in a rapidly changing industry.

Read Full Story at Benzinga โ†’
Advertisement
React:
Sources
Sponsored

More to Read

Udemy offers 20% discount on all courses with promo code inโ€ฆ
๐Ÿ’ฐ Business
Udemy offers 20% discount on all courses with promo code in November 2026
Wired ยท 15 days ago
Dana Incorporated raises full-year sales outlook to $7.8 biโ€ฆ
๐Ÿ’ฐ Business
Dana Incorporated raises full-year sales outlook to $7.8 billion
Nasdaq News ยท 13 days ago
Nvidia investigates CEO Jensen Huang's ties to alleged Chinโ€ฆ
๐Ÿ’ฐ Business
Nvidia investigates CEO Jensen Huang's ties to alleged Chinese spy
The Verge ยท 11 days ago
Nutritionists warn against late-night snacking for weight gโ€ฆ
๐Ÿฅ Health
Nutritionists warn against late-night snacking for weight gain risk
BBC Health ยท 14 days ago
Wired ranks top six VPN services for 2026 after extensive tโ€ฆ
๐Ÿ’ป Technology
Wired ranks top six VPN services for 2026 after extensive testing
Wired ยท 14 days ago
Quebec tenant shoots landlord Daniel Cloutier over rent disโ€ฆ
๐Ÿš” Crime & Justice
Quebec tenant shoots landlord Daniel Cloutier over rent dispute
Law & Crime ยท 14 days ago
Full view